|
|
Blood, 15 March 2006, Vol. 107, No. 6, pp. 2544-2547.
Prepublished online as a Blood First Edition Paper on November 22, 2005; DOI 10.1182/blood-2005-06-2601.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Brief report
c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma
Mauricio P. Oyarzo,
L. Jeffrey Medeiros,
Coralyn Atwell,
Marianna Feretzaki,
Vasiliki Leventaki,
Elias Drakos,
Hesham M. Amin, and
George Z. Rassidakis
From the Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
We hypothesized that inhibition of the FAS-mediated apoptosis pathway by FLICE-like inhibitory protein (c-FLIP) may contribute to oncogenesis in ALK+ anaplastic large-cell lymphoma (ALCL). Treatment with increasing concentrations of CH-11 (CD95/FAS agonistic antibody) had no effect on cell viability of 2 ALK+ ALCL cell lines, Karpas 299 and SU-DHL1, each expressing high levels of c-FLIP. However, inhibition of endogenous c-FLIP expression by specific c-FLIP siRNA in Karpas 299 and SU-DHL1 cells treated with CH-11 resulted in FAS-mediated cell death associated with increased annexin V binding, apoptotic morphology, and cleavage of caspase-8. In 26 ALK+ ALCL tumors, assessed for expression of DISC-associated proteins, CD95/FAS and c-FLIP were commonly expressed, in 23 (92%) of 25 and 21 (91%) of 23 tumors, respectively. By contrast, CD95L/FASL was expressed in only 3 (12%) of 26 ALCL tumors, although it was strongly expressed by surrounding small reactive lymphocytes. Our findings suggest that overexpression of c-FLIP protects ALK+ ALCL cells from death-receptor-induced apoptosis and may contribute to ALCL pathogenesis. (Blood. 2006;107:2544-2547)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Ambrogio, C. Martinengo, C. Voena, F. Tondat, L. Riera, P. F. di Celle, G. Inghirami, and R. Chiarle
NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells
Cancer Res.,
November 15, 2009;
69(22):
8611 - 8619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Shi, T. Tran, R. Sobkoviak, and R. M. Pope
Activation-induced Degradation of FLIPL Is Mediated via the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway in Macrophages
J. Biol. Chem.,
May 22, 2009;
284(21):
14513 - 14523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-D. Klemke, D. Brenner, E.-M. Weiss, M. Schmidt, M. Leverkus, K. Gulow, and P. H. Krammer
Lack of T-Cell Receptor-Induced Signaling Is Crucial for CD95 Ligand Up-regulation and Protects Cutaneous T-Cell Lymphoma Cells from Activation-Induced Cell Death
Cancer Res.,
May 15, 2009;
69(10):
4175 - 4183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Wang, W. Chen, W. Zeng, L. Bai, Y. Tesfaigzi, S. A. Belinsky, and Y. Lin
Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1156 - 1163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Perez, N. Parquet, K. Shain, R. Nimmanapalli, M. Alsina, C. Anasetti, and W. Dalton
Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP
J. Immunol.,
February 1, 2008;
180(3):
1545 - 1555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Yang, P. K. Epling-Burnette, J. S. Painter, J. Zou, F. Bai, S. Wei, and T. P. Loughran Jr
Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia
Blood,
February 1, 2008;
111(3):
1610 - 1616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
